2021
 

• Fair Pricing Coalition Welcomes Approval Of Two-Month HIV Prevention Shot; Denounces ViiV Healthcare’s Exorbitant, Unsustainable Pricing

2019 
 

• Fair pricing Coalition Urges Full Hearing of Legal Claims in Staley v. Gilead​
   

• Fair Pricing Coalition Welcomes Approval of ViiV’s Combination Tablet Dovato

​

2018

​​

• Fair Pricing Coalition Welcomes Approval of ViiV’sFair Pricing Coalition Pleased with Steps by Gilead to Increase Access to PrEP, but More Actions Needed
   

• Fair Pricing Coalition Disappointed at Launch Price of Janssen’s Protease Inhibitor-based Single-tablet Regimen Symtuza
   

• Fair Pricing Coalition Welcomes U.S. Launches of Mylan’s Tenofovir and Lamivudine Coformulation (Cimduo) and Efavirenz-based Single Tablet Regimens
   

• Letter to Gilead Sciences Opposing Unethical Patient Assistance Program Policy for Truvada for Post-exposure Prophylaxis

​

2017

​​

• FPC Welcomes FDA Approval of AbbVie’s New Pangenotypic HCV Combination Mavyret
   

• Health Affairs Blog Post Highlights Fair Pricing Coalition Recommendations to Modernize and Strengthen Existing Laws to Control Drug Costs
   

• Fair Pricing Coalition Troubled by Unjustified 2017 Drug Price Increases by HIV Pharmaceutical Manufacturers

​

2016

​

• FPC Releases New Report Urging Modernization of Existing Laws to Rein in Drug Pricing
   

• Open Letter to Manufacturers of HIV and Hepatitis Medications Opposing 2017 Price Increases

​

​